Lebel F - Search Results

1

Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial.

Le X, Cornelissen R, Garassino M, Clarke JM, Tchekmedyian N, Goldman JW, Leu SY, Bhat G, Lebel F, Heymach JV, Socinski MA. Le X, et al. Among authors: lebel f. J Clin Oncol. 2022 Mar 1;40(7):710-718. doi: 10.1200/JCO.21.01323. Epub 2021 Nov 29. J Clin Oncol. 2022. PMID: 34843401 Free PMC article. Clinical Trial.

2

Prolonged Central Nervous System Response in a Patient With HER2 Mutant NSCLC Treated With First-Line Poziotinib.

Tchekmedyian N, Paxton B, Lebel F, Keossayan L, Heymach JV. Tchekmedyian N, et al. Among authors: lebel f. JTO Clin Res Rep. 2020 Aug 7;1(4):100081. doi: 10.1016/j.jtocrr.2020.100081. eCollection 2020 Nov. JTO Clin Res Rep. 2020. PMID: 34589960 Free PMC article. No abstract available.

3

Carboplatin and Etoposide With or Without Palifosfamide in Untreated Extensive-Stage Small-Cell Lung Cancer: A Multicenter, Adaptive, Randomized Phase III Study (MATISSE).

Jalal SI, Lavin P, Lo G, Lebel F, Einhorn L. Jalal SI, et al. Among authors: lebel f. J Clin Oncol. 2017 Aug 10;35(23):2619-2623. doi: 10.1200/JCO.2016.71.7454. Epub 2017 Jun 12. J Clin Oncol. 2017. PMID: 28605291 Free article. Clinical Trial.

4

PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma.

Ryan CW, Merimsky O, Agulnik M, Blay JY, Schuetze SM, Van Tine BA, Jones RL, Elias AD, Choy E, Alcindor T, Keedy VL, Reed DR, Taub RN, Italiano A, Garcia Del Muro X, Judson IR, Buck JY, Lebel F, Lewis JJ, Maki RG, Schöffski P. Ryan CW, et al. Among authors: lebel f. J Clin Oncol. 2016 Nov 10;34(32):3898-3905. doi: 10.1200/JCO.2016.67.6684. Epub 2016 Sep 30. J Clin Oncol. 2016. PMID: 27621408 Clinical Trial.

5

Justification for a Fixed Dose of Eflapegrastim, a Long-Acting G-CSF, in Patients Receiving Docetaxel-Cyclophosphamide Chemotherapy.

Barrett JA, Greene D, Lakshmikanthan S, Kolli P, Chawla S, Lebel F. Barrett JA, et al. Among authors: lebel f. J Clin Pharmacol. 2021 Feb;61(2):204-210. doi: 10.1002/jcph.1723. Epub 2020 Aug 21. J Clin Pharmacol. 2021. PMID: 32827162 Clinical Trial.

6

Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial.

Chiocca EA, Yu JS, Lukas RV, Solomon IH, Ligon KL, Nakashima H, Triggs DA, Reardon DA, Wen P, Stopa BM, Naik A, Rudnick J, Hu JL, Kumthekar P, Yamini B, Buck JY, Demars N, Barrett JA, Gelb AB, Zhou J, Lebel F, Cooper LJN. Chiocca EA, et al. Among authors: lebel f. Sci Transl Med. 2019 Aug 14;11(505):eaaw5680. doi: 10.1126/scitranslmed.aaw5680. Sci Transl Med. 2019. PMID: 31413142 Free PMC article. Clinical Trial.

7

Eflapegrastim's enhancement of efficacy compared with pegfilgrastim in neutropenic rats supports potential for same-day dosing.

Barrett JA, Choi J, Lakshmikanthan S, Kim YY, Greene D, Kolli P, Song TH, Choi IY, Kim YH, Lebel F. Barrett JA, et al. Among authors: lebel f. Exp Hematol. 2020 Dec;92:51-61. doi: 10.1016/j.exphem.2020.09.199. Epub 2020 Sep 29. Exp Hematol. 2020. PMID: 33002567 Free article.

8

Plasma Pharmacokinetics of Veledimex, a Small-Molecule Activator Ligand for a Proprietary Gene Therapy Promoter System, in Healthy Subjects.

Cai H, Sun L, Miao J, Krishman S, Lebel F, Barrett JA. Cai H, et al. Among authors: lebel f. Clin Pharmacol Drug Dev. 2017 May;6(3):246-257. doi: 10.1002/cpdd.287. Epub 2016 Aug 4. Clin Pharmacol Drug Dev. 2017. PMID: 27364771 Clinical Trial.

9

Regulated intratumoral expression of IL-12 using a RheoSwitch Therapeutic System^® (RTS^®) gene switch as gene therapy for the treatment of glioma.

Barrett JA, Cai H, Miao J, Khare PD, Gonzalez P, Dalsing-Hernandez J, Sharma G, Chan T, Cooper LJN, Lebel F. Barrett JA, et al. Among authors: lebel f. Cancer Gene Ther. 2018 Jun;25(5-6):106-116. doi: 10.1038/s41417-018-0019-0. Epub 2018 May 14. Cancer Gene Ther. 2018. PMID: 29755109 Free PMC article.

10

Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteers.

Harb G, Lebel F, Battikha J, Thackara JW. Harb G, et al. Among authors: lebel f. Curr Med Res Opin. 2010 Feb;26(2):279-88. doi: 10.1185/03007990903432900. Curr Med Res Opin. 2010. PMID: 19947907 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

32 results

Search Page